, Volume 16, Issue 5, pp 374–375 | Cite as


Adis R&D Profile


  1. 1.
    Imutec Pharma Inc. Imutec Pharma receives marketing approval for Virulizin (Rm) for the treatment of malignant melanoma in Mexico. Media Release: [2 pages], 21 Oct 1997Google Scholar
  2. 2.
    Imutec Pharma Inc. Imutec Pharma announces positive phase I/II results for Virulizin (Rm). Media Release: [3 pages], 26 Aug 1998Google Scholar
  3. 3.
    Liu C, Mao H, Joshi SS, et al. A novel immunotherapeutic agent for pancreatic cancer: results of preclinial and clinical trials using virulizin. 90th Annual Meeting of the American Association for Cancer Research: 575, 10 Apr 1999Google Scholar
  4. 4.
    Imutec Pharma releases additional pancreatic cancer data; results of recent studies to support filings for pivotal trials. Business Wire [online]: [2 pages], 13 Nov 1998. Available from URL:
  5. 5.
    Lorus therapeutics Inc. Lorus’ Virulizin (Rm) demonstrates excellent anti-tumor activity in human breast cancer tumors in pre-clinical tests. Media Release: [2 pages], 9 Jan 2001. Available from URL:
  6. 6.
    Lorus Therapeutics Inc. Lorus Therapeutics virulizin — R — shows promise in lung, ovarian and prostate cancers. Media Release: [2 pages], 15 Aug 2001. Available from: URL:
  7. 7.
    Ferdinandi ES, Braun DP, Liu C, et al. Virulizin (Rm) — a review of its antineoplastic activity. Expert Opinion on Investigational Drugs 8: 1721–1735, Oct 1999PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations